Nektar Therapeutics (NKTR) : 7 analysts are covering Nektar Therapeutics (NKTR) and their average rating on the stock is 1, which is read as a Strong Buy. 7 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 3, which recommends a Hold affirms that they expect a large upside in the stock from the current levels.
Nektar Therapeutics (NKTR) : 6 investment research analysts covering Nektar Therapeutics (NKTR) have an average price target of $17.67 for the near short term. The highest target price given by the Brokerage Firm to the stock is $20 and the lowest target is $14 for the short term. Analysts expect the variance to be within $2.42 of the average price.
For this week, the average consensus of the company shares are rated as a Strong Buy. Nektar Therapeutics (NASDAQ:NKTR): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $17.08 and $16.91 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $17.32. The buying momentum continued till the end and the stock did not give up its gains. It closed at $17.21, notching a gain of 1.00% for the day. The total traded volume was 563,272 . The stock had closed at $17.04 on the previous day.
In a related news, Chess Robert, director of Nektar Therapeutics, unloaded 5,000 shares at an average price of $17.26 on August 1, 2016. The total amount of the transaction was worth $86,300, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.
Nektar Therapeutics is a clinical-stage biopharmaceutical company. The Company is engaged in the development of a pipeline of drug candidates that utilize its PEGylation and advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. The Companys pipeline is comprised of drug candidates for therapeutic areas, including oncology, pain, anti-infectives, and immunology. The Companys research and development activities involve small molecule drugs, peptides and other potential biologic drug candidates. Its drug candidates are designed to improve the pharmacokinetics, pharmacodynamics, half-life, bioavailability, metabolism or distribution of drugs and improve the overall benefits and use of a drug for the patient. Its polymer chemistry platform is being used to create specialized therapeutics, including small molecule oral and parenteral drugs, proteins, peptides and antibody fragments.